ProHealth health Vitamin and Natural Supplement Store and Health
Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|

Trending News

Gut Bacteria, Artificial Sweeteners and Glucose Intolerance

Culprits of Autism Identified: Toxins, Gut Bacteria, Nutritional Deficiencies, and Vaccines Made wit...

Vitamin E intake critical during 'the first 1,000 days'

Turmeric compound boosts regeneration of brain stem cells

Lower risk of mortality over thirteen year period in association with higher levels of vitamin D

Use of Broad-Spectrum Antibiotics Before Age 2 Associated with Obesity Risk

VIDEO: Beautiful Clouds - Relaxation and Meditation

Reverse Mitochondrial Damage

The Fast-Acting Solution for Healthy Digestive Function

Elevated plasma biomarkers of chronic inflammation in Gulf War illness

 
Print Page
Email Article

Citalopram Used to Treat Depression and Pain in Fibromyalgia Patients

  [ 1188 votes ]   [ Discuss This Article ]
By ImmuneSupport Staff • www.ProHealth.com • June 14, 2000



Summary

A study has tested the effects of citalopram and how it can be used to treat depression and pain in fibromyalgia (FM) patients.

Citalopram (brand name Celexa) is one of several anti-depressants in a class of drugs called SSRIs, or selective serotonin reuptake inhibitors. It has been documented in numerous clinical trials as effective and well-tolerated by patients. According to the deputy director of the New York State Psychiatric Institute in New York City, it has no known drug-drug interactions.

In the randomized, double-blind, placebo-controlled study, 40 female FM patients were given daily doses of citalopram. Placebos were given to 19 patients. (In a double-blind study, it is important to note that neither doctors or patients know who is given the drug versus the placebo.) Patients’ depression and physical health levels were assessed using the Visual Analogue Scales (VAS), the Montgomery Asberg Depression Rating Scale (MADRS), and the Fibrositis Impact Questionnaire (FIQ).

After just 1 month of treatment, citalopram helped alleviate depression – this result increased by the end of the trial. In fact, of the patients completing the test, 52.9% of the citalopram group noted improvement in overall feelings of well being, compared to only 22.2% of the placebo group.

After 2 months of treatment, citalopram had a significant effect on pain; however, after 4 months, no additional improvements were noted.


Abstract

Anderberg UM, Marteinsdottir I, von Knorring L
Department of Neuroscience Psychiatry, University Hospital, Uppsala University, Uppsala, Sweden

The effect of the selective serotonin reuptake inhibitor citalopram was studied in a randomized, double-blind, placebo-controlled, 4-month trial in patients with the fibromyalgia syndrome (FMS) who all fulfilled the American College of Rheumatology criteria. The citalopram doses varied between 20-40 mg daily. Forty female patients, 21 patients in the citalopram and 19 in the placebo group, participated. Assessment of pain, depressive symptoms and physical functioning were made using Visual Analogue Scales (VAS), the Montgomery Asberg Depression Rating Scale (MADRS) and the Fibrositis Impact Questionnaire (FIQ). In the global judgement of improvement, no significant changes were found between the citalopram and placebo groups as concerns pain or well-being, either in the Intention to Treat (ITT) analysis or in the completer analysis. However, among the completers, it was a tendency that more patients in the citalopram group (52.9%) were improved as compared to the placebo group (22.2%) concerning well-being. Furthermore, the results indicated that treatment with citalopram had a significant effect on pain on the VAS after 2 months of treatment compared to baseline. After 4 months, however, the effect had diminished. Measured with the FIQ, significant differences in the pain ratings were seen at the end of the trial. Significant effects on the depressive symptomatology measured by means of the MADRS were seen already after 1 month of treatment and were increasing further at the end of the trial, when a significant difference between the groups was also found.



Please Discuss This Article:   Post a Comment 



[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Save on Vitamins and Supplements

Featured Products

Vitamin D3 Extreme™ by ProHealth Vitamin D3 Extreme™ by ProHealth
50,000 IU Vitamin D3 - Prescription Strength
Optimized Curcumin Longvida® by ProHealth Optimized Curcumin Longvida® by ProHealth
Supports Cognition, Memory & Overall Health
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
FibroSleep™ by ProHealth FibroSleep™ by ProHealth
The All-in-One Natural Sleep Aid
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%

Natural Remedies

Reversing Neurodegeneration with a New Magnesium Compound Reversing Neurodegeneration with a New Magnesium Compound
Preserving Cognitive Function with Aging Preserving Cognitive Function with Aging
IBS, Crohn’s Disease, Colitis, and Other Digestive Disorders IBS, Crohn’s Disease, Colitis, and Other Digestive Disorders
Sleep Like a Baby in Nature's Cradle Sleep Like a Baby in Nature's Cradle
Fatigue & Fibro Fog: Could You Have a B-12 Deficiency? Fatigue & Fibro Fog: Could You Have a B-12 Deficiency?

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia 101
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS 101
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE
CONTACT US
PRIVACY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing